LONDON (Alliance News) - Epistem Holdings PLC saw its shares rise early Monday after it said it expects to imminently receive approval from Indian regulators for the launch of its Genedrive Tuberculosis and antibiotic resistance molecular diagnostic kit.
Epistem said it has been made aware that the Director General Of Health Services and the Ministry of Health and Family Welfare departments in India are to publish an approval letter in respect of the import licence for the kit.
It said a further update will be provided once the licence is formally approved.
Epistem shares were up 15% to 305.00 pence early Monday, one of the best performers in the AIM All-Share index.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.